Skip to main content
Erschienen in: Urologie in der Praxis 1/2019

24.01.2019 | Extended Abstract

Medikamentöse Therapie des benignen Prostatasyndroms – Chemie oder Pflanzen

verfasst von: Mustafa Tutal

Erschienen in: Urologie in der Praxis | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Auszug

Bei der Behandlung von Symptomen des unteren Harntraktes im Rahmen eines benignen Prostatasyndroms ist die medikamentöse Therapie eine rasch wirksame und effektive Therapieoption. Hierfür stehen zahlreiche synthetische Medikamente sowie Phytopharmaka zur Verfügung. Die synthetischen Therapeutika können einerseits in der Behandlung der akuten Symptome und andererseits bei einer nachhaltigen Reduktion der Krankheitsprogression wirksam sein. Bei milden bis moderaten Symptomen können Phytopharmaka eine Beschwerdelinderung bringen, bei nahezu nebenwirkungsfreier Anwendung. …
Literatur
1.
Zurück zum Zitat Gratzke C et al (2015) EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 67(6):1099–1109CrossRef Gratzke C et al (2015) EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 67(6):1099–1109CrossRef
2.
Zurück zum Zitat Michel MC, Vrydag W (2006) Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147(Suppl 2):S88–S119CrossRef Michel MC, Vrydag W (2006) Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147(Suppl 2):S88–S119CrossRef
3.
Zurück zum Zitat Barendrecht MM et al (2008) Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 27:226CrossRef Barendrecht MM et al (2008) Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 27:226CrossRef
4.
Zurück zum Zitat Chang DF et al (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31:664CrossRef Chang DF et al (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31:664CrossRef
5.
Zurück zum Zitat Oelke M, Höfner K, Berges RR, Jonas U (2002) Medikamentöse Therapie des benignen Prostatasyndroms mit α1-Rezeptorblockern. Urologe A 41:425–441CrossRef Oelke M, Höfner K, Berges RR, Jonas U (2002) Medikamentöse Therapie des benignen Prostatasyndroms mit α1-Rezeptorblockern. Urologe A 41:425–441CrossRef
6.
Zurück zum Zitat Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4‑year results from the CombAT study. Eur Urol 57:123–131CrossRef Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4‑year results from the CombAT study. Eur Urol 57:123–131CrossRef
7.
Zurück zum Zitat Naslund MJ et al (2007) A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 29:17CrossRef Naslund MJ et al (2007) A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 29:17CrossRef
8.
Zurück zum Zitat McConnell JD, Roehrborn CG, Bautista OM et al (2003) The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398CrossRef McConnell JD, Roehrborn CG, Bautista OM et al (2003) The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398CrossRef
9.
Zurück zum Zitat Gravas S, Oelke M (2010) Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 28:9–15CrossRef Gravas S, Oelke M (2010) Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 28:9–15CrossRef
10.
Zurück zum Zitat Ückert S, Oelke M (2011) Phospho-diesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 72:197–204CrossRef Ückert S, Oelke M (2011) Phospho-diesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 72:197–204CrossRef
11.
Zurück zum Zitat Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925CrossRef Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925CrossRef
12.
Zurück zum Zitat Oelke M, Giuliano F, Baygani SK et al (2014) Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic Hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU Int 114:568–575CrossRef Oelke M, Giuliano F, Baygani SK et al (2014) Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic Hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU Int 114:568–575CrossRef
13.
Zurück zum Zitat Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α‑blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003CrossRef Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α‑blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003CrossRef
14.
Zurück zum Zitat Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 296:2319–2328CrossRef Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 296:2319–2328CrossRef
15.
Zurück zum Zitat Chapple CR et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296CrossRef Chapple CR et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296CrossRef
16.
Zurück zum Zitat Oelke M, Martinelli E (2016) Medikamentöse Therapie des benignen Prostatasyndroms. Urologe 55:81–96CrossRef Oelke M, Martinelli E (2016) Medikamentöse Therapie des benignen Prostatasyndroms. Urologe 55:81–96CrossRef
17.
Zurück zum Zitat Barkin J, Guimaraes M, Jacobi G et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44:461–466CrossRef Barkin J, Guimaraes M, Jacobi G et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44:461–466CrossRef
18.
Zurück zum Zitat Casabé A, Roehrborn CG, Da Pozzo LF et al (2014) Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 191:727–733CrossRef Casabé A, Roehrborn CG, Da Pozzo LF et al (2014) Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 191:727–733CrossRef
19.
Zurück zum Zitat Glina S, Roehrborn CG, Esen A et al (2015) Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med 12:129–138CrossRef Glina S, Roehrborn CG, Esen A et al (2015) Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med 12:129–138CrossRef
21.
Zurück zum Zitat Madersbacher S et al (2008) Plant extracts: sense or nonsense? Curr Opin Urol 18:16CrossRef Madersbacher S et al (2008) Plant extracts: sense or nonsense? Curr Opin Urol 18:16CrossRef
23.
Zurück zum Zitat Bach D (2000) Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH- bedingten Miktionsbeschwerden. Urologe B 40:437CrossRef Bach D (2000) Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH- bedingten Miktionsbeschwerden. Urologe B 40:437CrossRef
24.
Zurück zum Zitat Berges R et al (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345:1529CrossRef Berges R et al (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345:1529CrossRef
25.
Zurück zum Zitat Klippel KF et al (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80:427CrossRef Klippel KF et al (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80:427CrossRef
26.
Zurück zum Zitat Wilt T et al (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev: Cd001043 Wilt T et al (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev: Cd001043
27.
Zurück zum Zitat Wilt T et al (2002) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev: Cd001044 Wilt T et al (2002) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev: Cd001044
28.
Zurück zum Zitat Carraro JC et al (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29:231CrossRef Carraro JC et al (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29:231CrossRef
29.
Zurück zum Zitat Safarinejad MR (2005) Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 5:1CrossRef Safarinejad MR (2005) Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 5:1CrossRef
30.
Zurück zum Zitat Lopatkin N et al (2005) Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World J Urol 23:139CrossRef Lopatkin N et al (2005) Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World J Urol 23:139CrossRef
31.
Zurück zum Zitat Sokeland J et al (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe 36:327CrossRef Sokeland J et al (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe 36:327CrossRef
32.
Zurück zum Zitat Vahlensieck W et al (2015) Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int 94:286CrossRef Vahlensieck W et al (2015) Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int 94:286CrossRef
33.
Zurück zum Zitat Morgia G et al (2014) Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate 74:1471CrossRef Morgia G et al (2014) Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate 74:1471CrossRef
34.
Zurück zum Zitat Sokeland J et al (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Alken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe A 36:327CrossRef Sokeland J et al (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Alken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe A 36:327CrossRef
Metadaten
Titel
Medikamentöse Therapie des benignen Prostatasyndroms – Chemie oder Pflanzen
verfasst von
Mustafa Tutal
Publikationsdatum
24.01.2019
Verlag
Springer Vienna
Erschienen in
Urologie in der Praxis / Ausgabe 1/2019
Print ISSN: 2661-8737
Elektronische ISSN: 2661-8745
DOI
https://doi.org/10.1007/s41973-019-0046-y

Weitere Artikel der Ausgabe 1/2019

Urologie in der Praxis 1/2019 Zur Ausgabe

Editorial

Editorial